interferon alpha + trivalent inactivated influenza vaccine

This investigational intranasal vaccine candidate consists of a trivalent inactivated influenza vaccine (TIV) combined with type I interferon (specifically alpha interferon) serving as a mucosal adjuvant. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), the formulation was intended to enhance the production of mucosal antibodies (IgA) in the respiratory tract to provide superior protection against influenza infection compared to standard vaccines. In a Phase 1 randomized trial (2006-2007 season), healthy adult volunteers received the vaccine intranasally with either 1 million or 10 million units of interferon alpha. While the adjuvant showed efficacy in preclinical mouse models by increasing antibody titers in nasal and lung secretions, the human clinical results indicated that the addition of interferon was well-tolerated but did not significantly improve immunogenicity over the vaccine alone.

Other names

Type 1 interferon as a mucosal adjuvant for influenza vaccineType1 interferon as a mucosal adjuvant for influenza vaccineType-1 interferon as a mucosal adjuvant for influenza vaccineIFN-alpha + TIVtype 1 interferon-National Institute of Allergy and Infectious Diseases (NIAID)-influenza